# US 9,517,258 B2 · Methods and materials for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,258 B2
- Document ID: US9517258B2
- Status: Granted
- Kind: B2
- Application number: 14/385,240
- Filed: 2013-03-15
- Published: 2015-03-05
- Granted: 2016-12-13
- Earliest claimed: 2012-03-15
- Assignees: Mayo Foundation for Medical Education and Research; University of Leeds
- Applicants: Mayo Foundation for Medical Education and Research; University of Leeds
- Inventors: Jose S. Pulido; Richard G. Vile; Timothy J. Kottke; Alan A. Melcher; Peter Selby
- Web page: https://patentgrep.com/patent/US9517258B2

## CPC

- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/53: {DNA (RNA) vaccination}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.

## Claims

### Claim 1

A method for identifying, from a second nucleic acid library, a nucleic acid encoding an antigen having the ability, in combination with at least two other antigens, to stimulate an anti-cancer response, wherein said second nucleic acid library is a library of virally-expressed nucleic acid members and has the ability to stimulate an anti-cancer response when administered to a mammal having cancer, wherein said method comprises:
(a) contacting immune cells with an aliquot of said second nucleic acid library to form a collection of virally infected cells, wherein said immune cells were obtained from a mammal that exhibited a reduction in the number of cancer cells following administration of a first nucleic acid library,
(b) obtaining a cell from said collection of virally infected cells that secretes an IL-17 polypeptide, wherein said cell contains a nucleic acid member of said second nucleic acid library, and
(c) determining the sequence of said nucleic acid member of said cell, wherein said nucleic acid member is said nucleic acid encoding an antigen having the ability, in combination with at least two other antigens, to stimulate an anti-cancer response.

### Claim 2 (depends on 1)

The method of claim 1, wherein said second nucleic acid library is a cDNA library.

### Claim 3 (depends on 1)

The method of claim 1, wherein said second nucleic acid library is a VSV-expressed cDNA library.

### Claim 4 (depends on 1)

The method of claim 1, wherein said first nucleic acid library is a cDNA library.

### Claim 5 (depends on 1)

The method of claim 1, wherein said first nucleic acid library is a VSV-expressed cDNA library or an expressed cDNA library via another virus, animal cell, bacterial cell, or fungus.

### Claim 6 (depends on 1)

The method of claim 1, wherein said second nucleic acid library and said first nucleic acid library are the same library.

### Claim 7 (depends on 1)

The method of claim 1, wherein said immune cells are lymph node cells and splenocytes.

### Claim 8 (depends on 1)

The method of claim 1, wherein said contacting step (a) comprises contacting said immune cells with said aliquot in the presence of an hsp70 polypeptide.

### Claim 9 (depends on 8)

The method of claim 8, wherein said hsp70 polypeptide is a human hsp70 polypeptide.

### Claim 10 (depends on 1)

The method of claim 1, wherein said aliquot comprises a multiplicity of infection (MOI) of less than 10.

### Claim 11 (depends on 1)

The method of claim 1, wherein said mammal is a rodent or primate.

### Claim 12 (depends on 1)

The method of claim 1, wherein said mammal is a mouse.

### Claim 13 (depends on 1)

The method of claim 1, wherein said mammal is a human.